Language:

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

The New England journal of medicine, 2018-02, Vol.378 (8), p.731-739 [Peer Reviewed Journal]

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1714448 ;PMID: 29466156

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Author: Drilon, Alexander ; Laetsch, Theodore W ; Kummar, Shivaani ; DuBois, Steven G ; Lassen, Ulrik N ; Demetri, George D ; Nathenson, Michael ; Doebele, Robert C ; Farago, Anna F ; Pappo, Alberto S ; Turpin, Brian ; Dowlati, Afshin ; Brose, Marcia S ; Mascarenhas, Leo ; Federman, Noah ; Berlin, Jordan ; El-Deiry, Wafik S ; Baik, Christina ; Deeken, John ; Boni, Valentina ; Nagasubramanian, Ramamoorthy ; Taylor, Matthew ; Rudzinski, Erin R ; Meric-Bernstam, Funda ; Sohal, Davendra P.S ; Ma, Patrick C ; Raez, Luis E ; Hechtman, Jaclyn F ; Benayed, Ryma ; Ladanyi, Marc ; Tuch, Brian B ; Ebata, Kevin ; Cruickshank, Scott ; Ku, Nora C ; Cox, Michael C ; Hawkins, Douglas S ; Hong, David S ; Hyman, David M
Subjects: Adolescent ; Adult ; Aged ; Analysis ; Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Antitumor activity ; Cancer ; Cancer therapies ; Child ; Child, Preschool ; Children ; Children & youth ; Diagnosis ; Disease-Free Survival ; Dosage and administration ; Drug dosages ; Female ; Humans ; Infant ; Inhibitor drugs ; Kaplan-Meier Estimate ; Male ; Medical research ; Middle Aged ; Neoplasms - chemistry ; Neoplasms - drug therapy ; Oncogene Proteins, Fusion - analysis ; Oncology ; Patients ; Protein Kinases - analysis ; Protein Kinases - genetics ; Pyrazoles - therapeutic use ; Pyrimidines - therapeutic use ; Receptor Protein-Tyrosine Kinases - antagonists & inhibitors ; Safety and security measures ; Survival ; Treatment outcome ; Tropomyosin ; Tumors ; Young Adult
Is Part Of: The New England journal of medicine, 2018-02, Vol.378 (8), p.731-739
Description: Fusions involving tropomyosin receptor genes are noted in cancers affecting children and adults. The TRK inhibitor larotrectinib induced a response in 75% of patients, regardless of age, tissue of origin, or TRK fusion partner. Toxic effects were generally mild.
Publisher: United States: Massachusetts Medical Society
Language: English
Identifier: ISSN: 0028-4793
EISSN: 1533-4406
DOI: 10.1056/NEJMoa1714448
PMID: 29466156
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list

Previous Result 19 Next Go to Next page


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1714448 ;PMID: 29466156

Searching Remote Databases, Please Wait